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Abstract
Subsequent to its discovery over 45 years ago, Epstein–Barr virus (EBV) has been associated with numerous human carcinomas.
Approximately 95% of the world’s population sustain an asymptomatic life-long EBV infection. EBV persists in the memory B cell pool
of normal healthy individuals and any disruption of this interaction results in virus-associated B cell tumours. The association of EBV
with epithelial cell tumours, speciﬁcally nasopharyngeal carcinoma and EBV-positive gastric carcinoma, is less clear and is currently con-
sidered to be a consequence of the aberrant establishment of virus latency in epithelial cells displaying pre-malignant genetic changes.
Although the precise role of EBV in the carcinogenic process is currently poorly understood, the presence of the virus in all tumour
cells provides opportunities for the development of novel therapeutic and diagnostic approaches. The study of EBV and its role in carci-
nomas continues to provide insights into the carcinogenic process that are relevant to a broader understanding of tumour pathogenesis
and to the development of targeted cancer therapies.
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Introduction
In 1958 Denis Burkitt, [1] a British surgeon, described a
novel tumour common to children in equatorial Africa that
was subsequently termed Burkitt’s lymphoma (BL). Originally,
it was hypothesized that BL was linked to an ‘arthropod-
borne’ infectious agent, owing to the fact that its geographi-
cal distribution was dependent on climatic factors [2]. In
1964, Epstein et al. [3] successfully used electron microscopy
to identify herpesvirus-like particles in a cell line established
from a BL biopsy, which was later classiﬁed as Epstein–Barr
virus (EBV) (also known as human herpesvirus-4). The causal
link between EBV and BL was corroborated by evidence
showing that BL patient sera had elevated antibodies to EBV
antigens [4]. This group also established a link between pri-
mary EBV infection and infectious mononucleosis [5] and,
subsequently, the association of EBV with the then-called
lymphoepithelioma, nasopharyngeal carcinoma (NPC) [6,7].
The oncogenic potential of EBV was further realized
through the association with numerous human malignancies.
In addition to endemic BL and NPC, EBV was later found
in a proportion of cases of Hodgkin’s lymphoma (HL),
post-transplant lymphoproliferative diseases, some T-cell
lymphomas and a proportion of cases of gastric carcinomas
(EBV-GC) [8]. Research is currently ongoing to determine
the role of EBV-encoded gene products in these different
cellular environments in an attempt to understand the role
that EBV plays in the pathogenesis of these malignancies.
Current knowledge about the biological properties of the
individual genes has been reviewed in detail by Young and
Rickinson [9].
Much of the known biology of EBV relates to its interac-
tion with B-lymphocytes. This is mainly a result of the ability
of EBV to readily infect and transform normal resting B-lym-
phocytes in vitro, which also conﬁrms the B-lymphotropic
nature of this virus. EBV latent gene expression in various
EBV-associated malignancies and EBV-derived cell lines has
led to the identiﬁcation of three different and distinct latency
programmes. These latency programmes are the result of
differential promoter activity and are inﬂuenced by host cell
factors.
Latency type 0: This is a controversial latency designation
with a putative role in EBV persistence in B cells, where
infected cells express no detectable latent mRNA or
proteins.
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Latency type I: As characterized by BL: the expression
of the EBV-encoded RNAs (EBERs) and the BamHI-A
rightward transcripts (BARTs) are observed in addition to
Qp promoter-induced EBV nuclear antigen-1 (EBNA1)
expression; the expression of all other EBNAs and the latent
membrane proteins-1, -2A and -2B (LMP1, LMP2A and
LMP2B) is not observed.
Latency type I: As characterized by NPC, EBV-GC and
EBV-positive HL: in addition to the expression of the EBERs,
BARTs and Qp promoter-driven EBNA1, the expression of
the latent membrane proteins (LMP1, LMP2A and LMP2B) is
detected to varying degrees; all other EBNAs are absent.
Latency type III: As characterized by lymphoblastoid cell
lines and post-transplant lymphoproliferative disease: the
full spectrum of latent gene products are expressed, which
includes EBNAs 1, 2, 3A, 3B, 3C and -LP that are spliced
from a single poly-cistronic transcript from the Cp/Wp
promoter, the expression of all three latent membrane
proteins (LMP1, LMP2A and LMP2B) and the EBER and
BART RNAs.
Although these classiﬁcations of latency are useful in deﬁn-
ing the different distinct gene expression programmes, they
are by no means completely deﬁnitive [10]. In recent years,
there has been increasing interest in the presence of differ-
ent viral and cellular micro-RNAs in EBV-infected B cells and
epithelial cells [11]. Roles for EBV-encoded micro-RNAs in
the transcriptional regulation of both the viral and cellular
genome have been described, but much more work is
required to characterize the function of these RNAs.
Both benign and malignant conditions, which vary in
severity, duration and pathology, are associated with EBV
[12]. The development of speciﬁc monoclonal antibodies to
viral proteins and sensitive in situ hybridization has allowed
the detection of both latent and lytic antigens and viral
DNA/RNA in these disease states. The contribution made
by EBV and the individual viral genes to the pathogenesis
of many of these malignancies is continuously being
explored. This review will concentrate on the evidence
available, supporting the association of EBV with epithelial
carcinomas.
EBV and Nasopharyngeal Carcinoma:
Epidemiology, Pathogenesis and Clinical
Implications
The World Health Organization (WHO) has classiﬁed NPC
into two main histological types: keratinizing squamous cell
carcinoma (WHO1) and non-keratinizing squamous cell
carcinoma (WHO2/3). The non-keratinizing type is further
subdivided into differentiated non-keratinizing (WHO2) and
undifferentiated carcinomas (WHO3) [13]. NPC is a tumour
of the surface epithelium, often presenting as a neck mass or
with symptoms of nasal obstruction and the loss of hearing.
The well differentiated keratinizing NPC (WHO1) accounts
for 20% of all NPC cases, whereas the remaining 80% of
non-keratinizing NPC cases are split between differentiated
and undifferentiated NPC. It is the WHO2 and WHO3 types
that are distinct from all other squamous cell carcinomas
because of their universal association with EBV. EBV exists in
a latent state in this undifferentiated carcinoma, exclusively
in the tumour cells, and absent from the surrounding lym-
phoid inﬁltrate [14,15]. However, the interaction between
the prominent lymphoid stroma and adjacent carcinoma cells
appears to be crucial for the continued growth of the malig-
nant NPC cells.
Similar to BL, NPC has a distinctive geographical distribu-
tion. NPC is most common in southern China, where it
accounts for approximately 20% of all adult cancers in this
region, with 25–30 cases per 100 000 population in Canton
and Hong Kong. NPC is very rare in Europe and North
America, where the incidence rate is <1 per 100 000 popula-
tion [16]. EBV-associated NPC have been identiﬁed in Eski-
mos as far aﬁeld as Alaska and Greenland. In 2000, 64 798
new cases were registered worldwide, with 80% of cases
being in China, Southeast Asia and other Asian countries
[17]. Interestingly, the incidence rates of NPC vary greatly
within the Chinese population, decreasing from south to
north, where approximately two or three cases per 100 000
population per year are observed among Chinese men in the
northernmost provinces [18].
The association of EBV with NPC was suggested when
serological studies identiﬁed a link between EBV and the
development of NPC [19,20]. Examination of DNA extracted
from undifferentiated NPC’s revealed that all cases, taken
from high, intermediate and low incidence areas, were
consistently positive for EBV [21]. In situ hybridization tech-
niques further conﬁrmed the presence of EBV DNA in the
tumour cells of virtually all low-grade differentiated or undif-
ferentiated tumours [7].
Many epidemiological studies have been performed
concerning NPC, and three well-deﬁned aetiological factors
involved in its pathogenesis have now been identiﬁed. These
include a genetic susceptibility in some individuals (particular
human leukocyte antigen haplotypes), an early-age exposure
to chemical carcinogens (particularly of Cantonese salted
ﬁsh) and an association with a latent EBV infection [22,23].
However, the incidence of NPC has begun to decline in the
past 25 years and this correlates with the declining use of
salted ﬁsh as part of children’s diet, further demonstrating
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that a combination of both environmental and genetic factors
contributes to the progression of NPC [16].
Analysis of EBV termini in NPC tumours has revealed
the presence of clonal EBV genomes, suggesting that these
carcinomas arise from the clonal expansion of a single EBV-
infected progenitor cell [24]. Similar to most EBV-associated
malignancies, the exact role of EBV in NPC pathogenesis
remains poorly deﬁned. The development and progression of
NPC involves the accumulation of a number of genetic
changes. Both genetic (e.g. gene ampliﬁcation, deletion and
mutation) and epigenetic (methylation) changes can affect the
development of NPC by altering the functions of genes that
are critical for proliferation, apoptosis, and differentiation
[25].
In NPC, EBV adopts a type II latency programme, similar
to that observed in EBV-positive HL (Fig. 1). Studies have
conﬁrmed the presence of LMP2A mRNA transcripts in a
high proportion of NPC cases [26,27], and such ﬁndings that
have been corroborated by the observation of LMP2A pro-
tein expression by immunohistochemistry in almost 50% of
NPC cases [28]. The presence of LMP1 in NPC tumours is
variable. Immunohistochemical and western blotting analysis
have conﬁrmed expression of LMP1 protein in 20–65% of
cases, whereas the use of more sensitive methods, including
nested RT-PCR, increases this number to >90% of cases
[26]. Interestingly, LMP1 expression in NPC is associated
with a better prognosis as a result of the ability of LMP1 to
induce the host immune responses [29,30]. Although NPC
tumours adopt a latent form of infection, the expression of
immediate early proteins, indicative of lytic replication, has
been detected in EBV-expressing tumour cells [31], suggest-
ing that low-level lytic replication can occur in NPC
tumours. Studies using real-time quantitative PCR to mea-
sure circulating tumour-derived EBV DNA in the blood of
NPC patients have shown that the level of pre-treatment
EBV DNA is strongly associated with overall survival, and
that post-treatment EBV DNA levels predict the progression
toward overall survival [32]. This approach is being applied
in large-scale screening trials as an approach for early
disease diagnosis.
The identiﬁcation of genetic changes in pre-malignant
lesions and NPC tumours has led to the proposal of a
multi-step model for the pathogenesis of NPC [14,15,25].
Genome-wide analyses of genetic alterations in NPC have
revealed consistent genetic losses at high frequencies on
multiple chromosomal arms, including 3p, 9p, 9q, 11q, 14q
and 16q. Recurrent chromosomal gains were also identiﬁed
on chromosomes 1q, 3q, 8q, 12p and 12q. The most com-
mon genetic change was the loss of chromosome regions
on 9p21 and 3p, which is thought to occur early during
NPC pathogenesis [33,34]. More recent ﬁndings showed
that the southern Chinese population in Hong Kong (a pop-
ulation at high risk for development of NPC) have a higher
frequency of 3p/9p losses in the normal nasopharyngeal epi-
thelium compared to the low-risk Chinese populations [16].
This leads to the conclusion that the elevated frequencies in
3p and 9q loss may predispose nasopharyngeal cells to facili-
tate latent EBV infection and this is a crucial event in the
multi-step progression towards NPC. Although the role that
these genetic alterations play in NPC pathogenesis remains
EBNA1EBERs
LMP2ALMP1
FIG. 1. Epstein–Barr virus (EBV) latent gene
expression in nasopharyngeal carcinoma
(NPC). In situ hybridization to the abundant
EBV-encoded EBV-encoded RNA (EBER) tran-
scripts (left, upper panel) is the standard
approach for detecting EBV infection in cells
and tissues. Immunohistochemical staining of
NPC conﬁrms EBV nuclear antigen-1 (EBNA1)
expression in every tumour cell (right, upper
panel). The expression of latent membrane
protein (LMP)1 and LMP2A in NPC biopsies
(lower panels) is more variable. Note the
prominent lymphoid inﬁltrate in NPC, which is
considered to contribute to the growth and
survival of the tumour cells.
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to be identiﬁed, the role that certain genes play has been
conﬁrmed. The introduction of either p16 or RASSF1A
(which are important in cell growth regulation and are
located on 9p and 3p, respectively) in the C666.1 NPC cell
line resulted in inhibition of cell growth, a marked reduction
in soft-agar colony formation, and, more importantly, a
reduction in the tumourigenic potential of cells in athymic
nude mice [35].
Taken together, these data suggest that, unlike EBV-associ-
ated B cell tumours, where the virus is considered to be an
initiating factor in the oncogenic process, virus infection in
the context of NPC pathogenesis behaves as a tumour-pro-
moting agent (Fig. 2). It is possible that EBV infection of nor-
mal differentiating epithelial cells results in virus replication,
whereas, in epithelial cells that are unable to differentiate
(perhaps as a consequence of genetic and epigenetic altera-
tions), EBV is able to establish a latent infection that contrib-
utes to malignant progression.
EBV and Gastric Carcinoma: Epidemiology,
Pathogenesis and Clinical Implications
Gastric carcinoma is the second most common carcinoma
worldwide [36] and is divided into two main types: gastric
cardia cancer, a cancer of the top inch of the stomach
where it meets the esophagus; and noncardia gastric cancer,
a cancer in all other areas of the stomach. Overall gastric
cancer incidence rates are decreasing, however; this decline
is mainly in noncardia gastric cancer rates. By contrast,
gastric cardia cancer rates are increasing, particularly in
Western countries such as the USA and many parts of
Europe. The large variations in incidence and mortality
suggest an important role of environmental factors in gastric
cancer risk.
The WHO reports that almost half of the world popu-
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FIG. 2. Schematic representation of the pathogenesis of nasopharyngeal carcinoma (NPC). This model highlights the multi-stepped process that
leads to the development of NPC. Epstein–Barr virus (EBV) infection alone cannot drive normal cells towards carcinoma development. It is
thought that loss of heterozygosity (LOH), possibly as a result of inherited traits (Chinese ethnicity) as well as exposure to dietary factors
(salted ﬁsh) and other environmental cofactors, is an early stage event in the pathogenesis of this disease. It is within these low-grade pre-inva-
sive lesions, subsequent to further genetic and epigenetic alterations, where EBV infection occurs. The expression of EBV latent genes provides
growth and survival advantages to these infected cells, ultimately leading to the development of NPC. Further genetic and epigenetic alterations
post-NPC development can occur, which may result in a more metastatic disease.
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establishes long-term infection of the gastric mucosa. Sub-
sequent to its discovery in 1982 by Warren and Marshall
(who were awarded the 2005 Nobel Prize in Medicine),
H. pylori has been associated with gastritis, peptic ulcer dis-
ease, mucosa-associated lymphoid tissue lymphoma and
gastric cancer. Almost 63% of noncardia gastric cancer
worldwide is a result of H. pylori infection. Despite the
strong association of H. pylori with gastric cancer, the
majority of infected individuals do not develop gastric can-
cer. This has prompted the search for bacterial, host and
environmental co-factors that explain why some infections
progress to gastric cancer.
EBV is associated with approximately 10% of more typical
gastric adenocarcinomas (GC), accounting for up to 90 000
new cases worldwide per year [37]. EBV-GC presents as
two histomorphologically distinct forms: a rare lymphoepi-
thelioma-like carcinoma, similar in appearance to NPC, and a
common gastric carcinoma type (glandular adenocarcinoma).
The relative ratio of the two types is 1 : 4 respectively, and,
similar to BL and NPC, is more frequent among males. RT-
PCR and in situ hybridization techniques were used to con-
ﬁrm the presence of EBV in almost 90% of gastric lymphoep-
ithelioma-like carcinoma cases, ranging in morphology from
the poorly and moderately differentiated tumours to the well
differentiated tumours [37]. EBV infection is observed to
occur mostly in the upper middle portions of the stomach
rather than the lower part of the stomach [38]. EBV infec-
tion is also associated with primary gastric carcinoma of the
lymphoepithelioma type [39,40].
There is signiﬁcant geographical variation in the associa-
tion of EBV with GC, which may be attributed to ethnic
and genetic differences. Gastric carcinoma is one of the
most common cancers in Japan, with approximately 7%
being EBV-positive gastric carcinomas. Epidemiological stud-
ies have suggested that EBV-GC is related to birth order,
high salt intake, and exposure to metal dust, although
these factors may vary geographically (e.g. between Japan
and Colombia), supporting the need for more detailed
investigation [41].
Similar to NPC, EBV-GC tumours display a type II latency
program of EBV latent gene expression [42]. EBV-GCs have
distinct phenotypic and clinical characteristics compared to
EBV-negative GC, including the loss of p16 expression, p73
promoter methylation, wild-type p53, a different pattern of
allelic loss, and improved patient survival [43–46]. As in
NPC, the precise role of EBV in the pathogenesis of gastric
carcinoma remains to be determined, although the absence
of EBV infection in premalignant gastric lesions supports the
contention that virus infection is a relatively late event in
gastric carcinogenesis [47].
Is EBV Associated with Other Common
Epithelial Malignancies?
A number of other more common carcinomas, such as
breast cancer [48] and liver cancer [49], have been reported
to be infected with EBV. Difﬁculties in conﬁrming these asso-
ciations have raised concerns about the use of PCR analysis
alone to deﬁne EBV association and about the speciﬁcity of
certain monoclonal antibody reagents. Deﬁnitive designation
of a tumour as ‘EBV-associated’ should require unequivocal
demonstration of the EBV genome or virus gene products
within the majority of the tumour cell population. This is not
the case with breast cancer, where it is clear that a small
and extremely variable proportion of tumour cells are sus-
ceptible to EBV infection in vivo, resulting in a low level lytic
EBV infection [50]. A subset of EBV-infected breast carci-
noma cells undergoing the virus lytic cycle may produce sol-
uble factors that are able to inﬂuence the growth and
survival of surrounding EBV-negative tumour cells, but this
remains to be demonstrated. The association of EBV with
liver cancer, which was originally described in Japanese cases,
has not been conﬁrmed in cases from Europe and the USA,
raising the possibility of geographical variation [51].
Conclusions
EBV was discovered over 45 years ago and its DNA was
fully sequenced in 1984. It remains the most common per-
sistent virus infection in humans, with over 95% of the pop-
ulation sustaining an asymptomatic life-long infection, which
is testimony to the intimate interaction between EBV and
the immune host. This relationship relies on the ability of
EBV to persist in the memory B cell pool of normal healthy
individuals and perturbation of this interaction results in
virus-associated B cell tumours. The association of EBV with
NPC and EBV-GC is less clear and may be a consequence
of the aberrant establishment of virus latency in epithelial
cells that have already undergone pre-malignant genetic
changes.
In striking contrast to EBV-infected B cells, epithelial cells
(of either primary or transformed origin) infected with EBV
are difﬁcult to maintain in continuous passage in vitro. Even
when successfully infected, transformed epithelial cell lines
tend to lose the EBV genome on serial passage. Therefore,
in vitro epithelial cell model systems have been generated
using recombinant strains of EBV with drug selectable mark-
ers to ascertain the impact of cellular and viral factors to the
persistence and stability of virus infection [52].
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Whatever the nature of these interactions and the precise
role of EBV in the carcinogenic process, there is clearly an
opportunity to exploit this association for the clinical beneﬁt
of patients. NPC is highly radiosensitive and there is a high
cure rate for those patients who are diagnosed early; there-
fore, mass screening programmes are underway in Hong
Kong to identify patients with early stages of NPC [53].
Alternative novel therapeutic approaches are currently being
explored with gene therapy [54] or therapeutic vaccinations
[55], showing promise for the ability to effectively target
EBV-associated carcinomas.
The strategy of choice when considering novel treatments
for EBV-associated epithelial carcinomas is to use an epi-
tope-based vaccination approach, which aims to boost EBV
speciﬁc cytotoxic T-lymphocyte responses to the infected
cells. This approach has already shown some promise using
LMP1 and LMP2 epitopes, as a polyepitope vaccine [56] or
using pulsed dendritic cells to boost the cytotoxic T-lympho-
cyte response [57]. These studies are paradigms for the
development of targeted cancer therapies and diagnostics,
and they further conﬁrm the far-reaching value of tumour
virology to the entire ﬁeld of cancer.
The study of EBV and its role in carcinomas continues to
provide insights into the carcinogenic process that are rele-
vant to a broader understanding of tumour pathogenesis and
the development of targeted cancer therapies.
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